According to filings with the U.S. Securities and Exchange Commission, Zetagen Therapeutics is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Tischler played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Zetagen Therapeutics
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMet, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable and ancillary osteologic treatments including, ZetaFuse, ZetaSet, ZetaDent and ZetaBase. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.

To learn more about Zetagen Therapeutics, visit http://www.zetagen.com/

Contact:
David Tischler, Chief Executive Officer
401-699-9402
https://www.linkedin.com/in/david-tischler-0638184/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.